FGF1 | Fibroblast growth factor 1 (acidic) | Cancer-related genes FDA approved drug targets RAS pathway related proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/17519/39213_A_4_6_rna_selected_60x60.jpg) | Group enriched |
MYOZ2 | Myozenin 2 | Disease related genes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/35764/77072_B_3_2_rna_selected_60x60.jpg) | Tissue enriched |
NT5C1A | 5'-nucleotidase, cytosolic IA | Enzymes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/54158/122566_B_9_7_rna_selected_60x60.jpg) | Group enriched |
POPDC3 | Popeye domain containing 3 | Predicted membrane proteins
| ![](/images/12514/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/12514/30777_B_9_1_rna_selected_60x60.jpg) | Group enriched |
SPTB | Spectrin, beta, erythrocytic | Disease related genes Plasma proteins
| | | | ![](/images/3394/10561_B_7_3_rna_selected_60x60.jpg) | Group enriched |
ATP1A3 | ATPase, Na+/K+ transporting, alpha 3 polypeptide | Disease related genes Enzymes Potential drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/33630/80314_A_2_7_rna_selected_60x60.jpg) | Group enriched |
CAMK2B | Calcium/calmodulin-dependent protein kinase II beta | Enzymes Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/26307/57633_A_5_8_rna_selected_60x60.jpg) | Group enriched |
FAM69C | Family with sequence similarity 69, member C | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/48928/110317_B_7_8_rna_selected_60x60.jpg) | Group enriched |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/21516/109609_B_7_2_rna_selected_60x60.jpg) | Group enriched |
MYO18A | Myosin XVIIIA | Cytoskeleton related proteins Plasma proteins
| | ![](/images/21121/if_selected_60x60.jpg) | ![](/images/21121/ihc_cell_selected_60x60.jpg) | ![](/images/19646/44139_B_7_7_rna_selected_60x60.jpg) | Group enriched |
S100A1 | S100 calcium binding protein A1 | Cancer-related genes Plasma proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2599/6674_B_4_1_rna_selected_60x60.jpg) | Group enriched |
SGCA | Sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) | Cytoskeleton related proteins Disease related genes Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/7537/22762_B_7_8_rna_selected_60x60.jpg) | Group enriched |
SGCG | Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) | Cytoskeleton related proteins Disease related genes Plasma proteins Predicted membrane proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/7476/21831_B_3_3_rna_selected_60x60.jpg) | Group enriched |
SMYD1 | SET and MYND domain containing 1 | Enzymes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/62282/145153_B_8_8_rna_selected_60x60.jpg) | Group enriched |
CORO6 | Coronin 6 | | ![](/images/21556/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/21556/48471_A_7_4_rna_selected_60x60.jpg) | Group enriched |
FHL2 | Four and a half LIM domains 2 | | | | | ![](/images/6028/18426_B_8_8_rna_selected_60x60.jpg) | Group enriched |
GRM1 | Glutamate receptor, metabotropic 1 | Disease related genes G-protein coupled receptors Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | ![](/images/15701/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/15701/35577_B_7_4_rna_selected_60x60.jpg) | Group enriched |
MTUS2 | Microtubule associated tumor suppressor candidate 2 | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/31475/67454_B_9_1_rna_selected_60x60.jpg) | Tissue enriched |
SH3RF2 | SH3 domain containing ring finger 2 | | ![](/images/58119/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/58119/145981_B_3_5_rna_selected_60x60.jpg) | Group enriched |
ZNF106 | Zinc finger protein 106 | Plasma proteins
| ![](/images/54267/ihc_selected_60x60.jpg) | | | ![](/images/54267/121437_B_8_4_rna_selected_60x60.jpg) | Group enriched |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/67972/149849_A_9_5_rna_selected_60x60.jpg) | Tissue enhanced |
AKAP6 | A kinase (PRKA) anchor protein 6 | Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/48741/138677_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
ALPK2 | Alpha-kinase 2 | Cancer-related genes Enzymes
| ![](/images/28084/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/29801/63981_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
BVES | Blood vessel epicardial substance | Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18176/42358_B_2_1_rna_selected_60x60.jpg) | Tissue enhanced |
C1orf170 | Chromosome 1 open reading frame 170 | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/31711/142468_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
C1QTNF9 | C1q and tumor necrosis factor related protein 9 | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/56632/128770_B_8_8_rna_selected_60x60.jpg) | Tissue enhanced |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/39796/84042_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
CDH13 | Cadherin 13 | Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/25863/55048_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
CDH2 | Cadherin 2, type 1, N-cadherin (neuronal) | CD markers Plasma proteins Predicted membrane proteins
| | | | ![](/images/58574/142433_B_8_7_rna_selected_60x60.jpg) | Tissue enhanced |
CLGN | Calmegin | Predicted membrane proteins Predicted secreted proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/20709/46834_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
CRYAB | Crystallin, alpha B | Cancer-related genes Disease related genes Predicted membrane proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/2053/5498_A_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
DKK3 | Dickkopf WNT signaling pathway inhibitor 3 | Plasma proteins Predicted secreted proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/11868/28132_B_9_4_rna_selected_60x60.jpg) | Tissue enhanced |
FAM110B | Family with sequence similarity 110, member B | | ![](/images/8318/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/8318/22607_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
FILIP1 | Filamin A interacting protein 1 | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/53564/130394_A_3_2_rna_selected_60x60.jpg) | Tissue enhanced |
HSPB2-C11orf52 | HSPB2-C11orf52 readthrough (NMD candidate) | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/38889/83408_A_8_8_rna_selected_60x60.jpg) | Tissue enhanced |
HSPB8 | Heat shock 22kDa protein 8 | Disease related genes
| | | ![](/images_static/rna_center.gif) | ![](/images/15876/36801_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
MASP1 | Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/1617/ihc_cell_selected_60x60.jpg) | ![](/images/1617/7280_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
NDRG4 | NDRG family member 4 | Predicted membrane proteins
| | ![](/images/15313/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/15313/35605_A_4_8_rna_selected_60x60.jpg) | Tissue enhanced |
NEBL | Nebulette | | | ![](/images/13995/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/13994/32941_B_9_7_rna_selected_60x60.jpg) | Tissue enhanced |
NES | Nestin | Plasma proteins
| | | | ![](/images/26111/58724_A_1_6_rna_selected_60x60.jpg) | Tissue enhanced |
OXCT1 | 3-oxoacid CoA transferase 1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted secreted proteins
| | | | ![](/images/12047/28141_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| ![](/images/14492/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/14492/34301_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
PKP2 | Plakophilin 2 | Disease related genes Plasma proteins
| ![](/images/14314/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/14314/33518_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
PLN | Phospholamban | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | ![](/images/26900/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/26900/58116_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |
PPFIA4 | Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4 | Plasma proteins
| | | ![](/images/53419/ihc_cell_selected_60x60.jpg) | ![](/images/54132/129210_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |
RAB9B | RAB9B, member RAS oncogene family | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/61932/140273_B_7_5_rna_selected_60x60.jpg) | Tissue enhanced |
RP11-849F2.7 | KRAB-A domain-containing protein 2 | | | ![](/images/30449/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/30449/64093_B_7_7_rna_selected_60x60.jpg) | Tissue enhanced |
RRAD | Ras-related associated with diabetes | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/41755/113224_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
SGSM1 | Small G protein signaling modulator 1 | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/3986/12493_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
SLC2A4 | Solute carrier family 2 (facilitated glucose transporter), member 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/16544/ihc_cell_selected_60x60.jpg) | ![](/images/16544/35881_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |